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ABSTRACT 
 
Background The medical care of patients with acute stroke varies considerably 
between countries which could lead to measurable differences in mortality and 
functional outcome. 
Methods All 1,484 patients from 11 countries who were enrolled into the ‘Tinzaparin 
in Acute Ischaemic Stroke Trial’ (TAIST) were included in this sub-study. Prospectively 
collected information on demographics, risk factors, clinical features, measures of 
service quality (e.g. admission to stroke unit), and outcome were assessed. Outcomes 
were adjusted for treatment assignment, case mix and service relative to the British 
Isles. 
Results Differences in case mix (mostly minor in magnitude) and clinical service 
(many of prognostic relevance) were present between the countries. Significant 
differences in outcome were present between the countries. When assessed by 
geographical region, death or dependency were lower in North America (odds ratio 
adjusted for treatment group only, OR 0.52, 95% confidence intervals, 95% CI 0.39-
0.71) and North West Europe (OR 0.54, 95% CI 0.37-0.78) relative to the British 
Isles; similar reductions were seen when adjustments were made for 11 case mix 
variables and 5 service quality measures. Similarly, case fatality rates were lower in 
North America (OR 0.44, 95% CI 0.30-0.66) and Scandinavia (OR 0.50, 95% CI 0.33-
0.74) relative to the British Isles whether crude or adjusted for case mix and service 
quality. 
Conclusions Both functional outcome and case fatality vary considerably between 
countries, even when adjusted for prognostic case mix variables and measures of 
good stroke care. Differing health care systems, and the management of patients with 
acute stroke, may contribute to these findings. 
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INTRODUCTION 
 
Outcome and the incidence of stroke vary between different countries,[1-3] variations 
in case mix, including demographics (age, gender) and the prevalence of vascular risk 
factors explain some of these differences.[4-6] Disparities in outcome may also result 
from variations in medical practice, e.g. the use of stroke units which are known to 
reduce death and disability,[7] and the treatment of acute stroke.[8] Finally, different 
processes of care may also be important, e.g. hospitalisation rates for stroke differ 
across various countries.[9] 
 
Within the western world it might be expected that functional outcome, corrected for 
case mix and service provision, would be similar. However, evidence suggests that 
this may not be the case. In a study comparing outcome in 12 centres (22 hospitals) 
in 7 European countries, outcome varied twofold when adjusted for case mix and use 
of health service resources.[8] Analysis of functional outcome in the ‘International 
Stroke Trial’ revealed similar findings.[10] In both studies, outcome was worst in the 
UK.[8, 10] In contrast, functional outcome was not significantly different between 
countries when corrected for case mix and health care resource use in the GAIN trial, 
despite significant variations in unadjusted case fatality.[11] 
 
We compared case mix, clinical management and functional outcome between eleven 
countries to further assess this question using data from the ‘Tinzaparin in Acute 
Ischaemic Stroke Trial’ (TAIST).[12] 
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METHODS 
 
TAIST 
The ‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST) compared the safety and 
efficacy of tinzaparin (low molecular weight heparin) given at high dose (175 anti-Xa 
IU/kg/day), tinzaparin at medium dose (100 anti-Xa IU/kg/day), and aspirin (300 mg 
od) in patients with acute ischaemic stroke.[12] The principal investigators from the 
100 centres participating in TAIST were experienced in taking part in acute stroke 
trials. All information was collected prospectively as part of the trial protocol. 
 
Case mix/prognostic factors 
Case mix variables included demographic - age, gender, race; vascular risk factors - 
smoking, history of hypertension, diabetes mellitus, stroke, myocardial infarction; pre-
morbid dependency (mRS); stroke syndrome; severity – Scandinavian Neurological 
Stroke Scale (SNSS); systolic blood pressure; investigations - atrial fibrillation on 
ECG, visible infarct on CT; time to randomisation;  and pre-stroke prevention - aspirin, 
anticoagulation, anti-hypertensive therapy, lipid-lowering therapy. 
 
Clinical management 
The use of evidence-based interventions in hospital was recorded: admission to an 
Acute Stroke Unit (ASU) and/or Stroke Rehabilitation Unit (SRU), application of 
venous compression stockings, treatment by a physiotherapist and/or speech and 
language therapist, and secondary prevention (aspirin, anticoagulation, anti-
hypertensive therapy, lipid-lowering therapy). 
 
Outcomes 
Outcome was determined as combined death or dependency - modified Rankin Scale 
(mRS) greater than two, measured at day 180 and recorded by face-to-face interview, 
length of stay in hospital, and discharge disposition. 
 
Country and geographical region 
Outcome was assessed by the 11 participating countries and aggregates of these 
defined by geographical region and similarity of health care system: British Isles 
(Ireland, UK), Franco (Belgium, France); North America (Canada), North-West Europe 
(Germany, Netherlands), and Scandinavia (Denmark, Finland, Norway, Sweden). 
 
Definitions 
TAIST used the following definitions for stroke units: an Acute Stroke Unit (ASU) - 
‘high-dependency nursing unit (or area) caring only/mainly for patients with acute 
stroke and providing close monitoring of neurological and vascular signs’;[12] Stroke 
Rehabilitation Unit (SRU) - ‘dedicated rehabilitation unit (or area) caring only/mainly 
for patients with recent stroke and providing multi-disciplinary therapy (e.g. 
physiotherapy, occupational therapy, speech & language therapy)’.[12] 
 
Statistical analysis 
Prognostic case mix factors, clinical management factors, and outcomes were 
compared by country and geographical region, using chi square tests in the case of 
categorical data and Kruskal-Wallis tests for continuous data. Models utilising logistic 
regression and Cox proportional hazard approaches were developed using variables 
known to be of prognostic significance.[13] The likelihood test was used for assessing 
homogeneity. All analyses were performed using SAS (SAS Inst., USA). Significance 
was taken at p<0.05 and 95% confidence intervals are given. 
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RESULTS 
 
Subjects 
1,499 patients were randomised, however emerging exclusion criteria prevented 
treatment in 15 patients. Analyses were performed on the 1,484 patients with acute 
ischaemic stroke who received at least one randomised treatment with tinzaparin or 
aspirin.[12] The number of patients enrolled by country varied between 27 (Finland) 
and 388 (Canada, table 1). Significant statistical differences in the demographic and 
clinical characteristics of enrolled patients (except gender and the incidence of 
previous stroke) existed between the countries (table 1), including: pre-morbid 
independence (mRS=0, Denmark 57.3%, France 88.5%), previous hypertension 
(Norway 32.9%, Belgium 67.5%), atrial fibrillation (Finland 0.0%, Ireland 26.2%), 
and total anterior circulation infarct (Germany 2.8%, Finland 63.0%). Similarly, the 
prevalence of pre-stroke vascular prophylaxis varied between countries (table 2), e.g. 
lipid lowering therapy (Finland 0.0%, Belgium 22.5%%). 
 
 
 6 
TABLE 1 
 
Baseline demographics, risk factors and clinical measures by country. Mean (SD) or frequency (%); comparison by Chi Square test 
or Kruskal-Wallis test. 
 
Country 
 
Belgium Canada Denmark Finland France Germany Ireland Nether 
lands 
Norway Sweden UK Total p 
Subjects 
 
40 388 110 27 191 36 61 143 82 123 283 1484  
Centres 
 
4 27 6 4 18 4 4 6 5 7 15 100  
Age (yr) 
 
72.8 
(8.8) 
70.8 
(11.2) 
72.4 
(11.7) 
69.6 
(10.6) 
70.1 
(12.4) 
70.7 
(10.3) 
70.3 
(12.1) 
71.8 
(10.8) 
75.3 
(7.9) 
74.8 
(8.1) 
71.1 
(11.0) 
71.6 
(11.0) 
0.001
2 
Gender 
(male, %) 
22  
(55.0) 
218 
(56.2) 
58  
52.7) 
16 
(59.3) 
113 
(59.2) 
19  
(52.8) 
33 
(54.1) 
67  
(46.9) 
48 
(58.5) 
68  
(55.3) 
145 
(51.2) 
807 
(54.4) 
0.66 
Race, 
white (%) 
40  
(100) 
356 
(91.8) 
110 
(100) 
27  
(100) 
186 
(97.4) 
36  
(100) 
61  
(100) 
139 
(97.2) 
82  
(100) 
123 
(100) 
269 
(95.1) 
1429 
(96.3) 
0.000
2 
Current 
smoking 
(%) 
11  
(27.5) 
116 
(29.9) 
50  
(45.5) 
4  
(14.8) 
27  
(14.1) 
6  
(16.7) 
18  
(29.5) 
35  
(24.5) 
20  
(24.4) 
20 
 (16.3) 
75 
 
(26.5) 
382 
(25.7) 
<0.0
001 
Previous 
HT (%) 
27  
(67.5) 
225 
(58.0) 
38  
(34.5) 
14  
(51.9) 
100 
(52.4) 
22  
(61.1) 
33  
(54.1) 
68  
(47.6) 
27  
(32.9) 
54  
(43.9) 
119 
(42.0) 
727 
(49.0) 
<0.0
001 
Previous 
DM (%) 
7  
(17.5) 
97  
(25.0) 
17  
(15.5) 
6  
(22.2) 
35  
(18.3) 
5  
(13.9) 
6  
(9.8) 
20  
(14.0) 
7  
(8.5) 
18  
(14.6) 
32  
(11.3) 
250 
(16.8) 
0.000
2 
Previous 
MI (%) 
5  
(12.5) 
90  
(23.2) 
12  
(10.9) 
6  
(22.2) 
12  
(6.3) 
2  
(5.6) 
8 
(13.1) 
15  
(10.5) 
14  
(17.1) 
22  
(17.9) 
46  
(16.3) 
232 
(15.6) 
<0.0
001 
Previous 
stroke 
(%) 
5  
(12.5) 
58  
(15.9) 
11  
(10.0) 
2 
(7.4) 
10  
(5.2) 
5  
(13.9) 
7  
(11.5) 
18  
(12.6) 
12  
(14.6) 
17  
(13.8) 
48  
(17.0) 
193 
(13.0) 
0.06 
Premorbid 
mRS (=0, 
%) 
24  
(60.0) 
295 
(76.0) 
63  
(57.3) 
22  
(81.5) 
169 
(88.5) 
26  
(72.2) 
39  
(63.9) 
104 
(72.7) 
55 
(67.1) 
76  
(61.8) 
179 
(63.3) 
1052 
(70.9) 
<0.0
001 
OCSP type 
(TACI, %) 
25  
(62.5) 
97  
(25.0) 
21  
(19.1) 
17  
(63.0) 
65  
(34.0) 
1  
(2.8) 
34  
(55.7) 
66  
(46.2) 
25  
(30.5) 
52  
(42.3) 
119 
(42.0) 
522 
(35.2) 
<0.0
001 
SSS 30.3 34.8 36  31.9 29.4 36.1 28.6 30.4 35.5 32.5 30.0 32.3 <0.0
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(12.8) (12.4) (11.8) (13.1) (13.7) (11.6) (11.8) (12.3) (10.0) (13.1) (13.1) (12.8) 001 
SBP 
(mmHg) 
 
152.2 
(19.6) 
153.8 
(21.9) 
162.8 
(24.2) 
154.7 
(18.6) 
157.0 
(23.5) 
159.2 
(19.0) 
155.2 
(20.0) 
157.8 
(23.7) 
157.2 
(19.9) 
163.3 
(21.0) 
153.0 
(23.0) 
156.2 
(22.4) 
0.000
1 
AF on ECG 
(%)  
1  
(2.5) 
26  
(6.7) 
10  
(9.1) 
0 
(0) 
18  
(9.4) 
3  
(8.3) 
16  
(26.2) 
16  
(11.2) 
8  
(9.8) 
31  
(25.2) 
52  
(18.4) 
181 
(12.2) 
<0.0
001 
Infarct on 
CT (%)  
14  
(35.0) 
230 
(59.3) 
76  
(69.1) 
21  
(77.8) 
91 
(47.6) 
26  
(72.2) 
38  
(62.3) 
78  
(54.5) 
41 
(50.0) 
81  
(65.9) 
201 
(71.0) 
897 
(60.4) 
<0.0
001 
Time to 
randomisa
tion (hr) 
24.2 
(13.0) 
25.8 
(13.1) 
28.6 
(12.9) 
28.9 
(13.4) 
21.7 
(12.9) 
16.1 
(9.8) 
31.1 
(11.4) 
22.3 
(11.9) 
28.7 
(11.9) 
24.4 
(11.7) 
30.6 
(13.6) 
26.1 
(13.2) 
<0.0
001 
 
AF: atrial fibrillation; DM: diabetes mellitus; HT: hypertension; MI: myocardial infarction; OCSP: Oxford Community Stroke 
Project; SBP: systolic blood pressure; SSS: Scandinavian Stroke Scale (range 0-58) 
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Clinical practice 
In-hospital care varied considerably between countries, including (table 2): admission 
to a SRU (Finland 0.0%, Netherlands 67.1%), use of venous compression stockings 
(Sweden 13.0%, Netherlands 94.4%), and management by a speech and language 
therapist (Sweden 13.8%, Ireland 62.3%). Similarly, secondary prevention rates 
differed significantly between countries (table 2): anticoagulation in patients with 
presumed cardio-embolic stroke (Netherlands 3.6%, Finland 100.0%), and anti-
platelet treatment in non-cardioembolic stroke (Belgium 57.1%, Norway 84.9%).
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TABLE 2 
 
Clinical management prior to, during and after acute ischaemic stroke by country. Number (%); comparison by Chi-square test or 
Kruskal-Wallis test. 
 
Country Belgium Canada Denmark Finland France Ger 
many 
Ireland Nethe
r 
lands 
Norway Swede
n 
UK Total p 
Subjects 40 388 110 27 191 36 61 143 82 123 283 1484  
Pre-stroke              
Antiplatelet 
(%) 
2  
(5.0) 
1  
(0.3) 
0  
(0) 
2  
(7.4) 
1  
(0.5) 
2  
(5.6) 
0  
(0) 
8  
(5.6) 
0  
(0) 
5  
(4.1) 
3  
(1.1) 
24  
(1.6) 
<0.0001 
Anticoagulation 
(%) 
0  
(0) 
1  
(0.3) 
2  
(1.8) 
0  
(0) 
0 
 (0) 
0  
(0) 
0  
(0) 
0  
(0) 
0  
(0) 
1  
(0.8) 
0 
(0) 
4  
(0.3) 
0.28 
Antithrombotic 
(%) 
2  
(5.0) 
2  
(0.5) 
2  
(1.8) 
2  
(7.4) 
1  
(0.5) 
2  
(5.6) 
0  
(0) 
8  
(5.6) 
0  
(0) 
6  
(4.9) 
3  
(1.1) 
28  
(1.9) 
0.0001 
Anti 
hypertensive 
(%) 
28  
(70) 
186 
(47.9) 
45  
(40.9) 
12  
(44.4) 
97  
(50.8) 
17  
(47.2) 
31  
(50.8) 
70  
(48.9) 
35  
(42.7) 
63  
(51.2) 
98  
(34.6) 
682 
(46.0) 
0.0008 
Lipid lowering 
(%) 
9  
(22.5) 
32  
(8.3) 
1  
(0.9) 
0  
(0) 
20  
(10.5) 
1  
(2.8) 
2  
(3.3) 
18  
(12.6) 
2  
(2.4) 
8  
(6.5) 
7  
(2.5) 
100  
(6.7) 
<0.0001 
In-hospital              
Acute Stroke 
Unit (%) 
5 
(12.5) 
60  
(15.5) 
42  
(38.2) 
4  
(14.8) 
45  
(23.6) 
13  
(36.1) 
1  
(1.6) 
68  
(47.8) 
53  
(64.6) 
56  
(45.5) 
225 
(79.5) 
572 
(38.5) 
<0.0001 
Stroke 
Rehabilitation 
Unit (%) 
16  
(40.0) 
84 
(21.6) 
63  
(57.3) 
0  
(0) 
1  
(0.5) 
24  
(66.7) 
3  
(4.9) 
96  
(67.1) 
32  
(39.0) 
55  
(44.7) 
80  
(28.3) 
454 
(30.6) 
<0.0001 
Stroke Unit 
(%) 
17  
(42.5) 
141 
(36.3) 
90  
(81.8) 
4  
(14.8) 
45  
(23.6) 
29  
(80.6) 
4  
(6.6) 
113 
(79.0) 
82 
(100) 
96  
(78.0) 
234 
(82.7) 
855 
(57.6) 
<0.0001 
Compression 
stockings (%) 
35  
(87.5) 
149 
(38.4) 
15  
(13.6) 
6  
(22.2) 
118 
(61.8) 
29  
(80.6) 
41  
(67.2) 
135 
(94.4) 
13  
(15.9) 
16 
(13.0) 
246 
(86.9) 
803 
(54.1) 
<0.0001 
Physiotherapy 
(%) 
34  
(85.0) 
326 
(84.0) 
98  
(89.1) 
23  
(85.2) 
168 
(88.0) 
34  
(94.4) 
52  
(85.2) 
127 
(88.8) 
78  
(95.1) 
102 
(82.9) 
249 
(88.0) 
1291 
(87.0) 
0.0009 
Speech 
therapy (%) 
17  
(42.5) 
171 
(44.1) 
28  
(25.5) 
9  
(33.3) 
32  
(16.8) 
19  
(52.8) 
38  
(62.3) 
50  
(35.0) 
18  
(22.0) 
17  
(13.8) 
138 
(48.8) 
537 
(36.2) 
<0.0001 
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Post-stroke              
Antiplatelet* 
(%) 
16  
(57.1) 
207 
(64.7) 
70  
(76.1) 
19  
(76.0) 
91  
(64.5) 
20  
(80.0) 
22  
(73.3) 
89  
(78.8) 
56  
(84.9) 
67  
(84.8) 
141 
(77.5) 
798 
(72.5) 
0.0001 
Anti 
coagulation† 
(%) 
3  
(25.0) 
23  
(35.4) 
3  
(20.0) 
2  
(100.0) 
4  
(8.2) 
2  
(18.2) 
9  
(29.0) 
1  
(3.6) 
7  
(53.9) 
7  
(15.9) 
22  
(22.5) 
83  
(22.6) 
0.0002 
Anti 
thrombotic 
(%) 
19  
(47.5) 
230 
(59.7) 
73  
(68.2) 
21  
(77.8) 
95  
(50.0) 
22  
(61.1) 
31  
(50.8) 
90  
(63.8) 
63  
(79.8) 
74  
(60.2) 
163 
(58.2) 
881 
(60.0) 
0.0002 
Anti 
hypertensive 
(%) 
22  
(55.0) 
216 
(55.7) 
46  
(41.8) 
11  
(40.7) 
97  
(50.8) 
21  
(58.3) 
24  
(39.3) 
53  
(37.1) 
39  
(47.6) 
66  
(53.7) 
108 
(38.2) 
703 
(47.4) 
0.0001 
Lipid lowering 
(%) 
8  
(20.0) 
63  
(16.2) 
4  
(2.8) 
0  
(0) 
25  
(13.1) 
1  
(2.8) 
10  
(16.4) 
22  
(15.4) 
5  
(6.1) 
15  
(12.2) 
34  
(12.0) 
187 
(12.6) 
0.0028 
 
*% anticoagulation = number on anticoagulant / number with presumed cardioembolic ischaemic stroke 
†% antiplatelet = number on antiplatelet / number with presumed non-cardioembolic ischaemic stroke 
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Functional outcome 
The eleven countries differed in each measure of outcome (table 3), including 
combined death and dependency at day 180 (mRS>2, Germany 44.4%, Ireland 
67.2%), length of stay in hospital (Denmark/Finland 11 days, Ireland 39 days), and 
discharge to an institution.  
 
The following case mix variables were associated with a poor outcome in univariate 
analyses: increasing age, female gender, pre-morbid disability (mRS 1,2), non-
smoker, history of previous stroke, diabetes mellitus, high blood pressure, atrial 
fibrillation, increasing stroke severity (SSS), and visible infarction on the baseline CT 
scan (data not shown). Measures of clinical care were also associated with a poor 
outcome: non-admission to a SRU, care by a physiotherapist and/or speech therapist, 
and use of compression stockings. Functional outcome was not related to race, time to 
treatment, admission to an ASU, or treatment with tinzaparin versus aspirin (data not 
shown). When assessing the effect of treatment on functional outcome by country, 
comparisons of tinzaparin versus aspirin did not differ apart from for German patients 
where tinzaparin was inferior to aspirin.  
 
The odds of being dead or dependent (mRS >2) at 6 months were significantly lower 
in Canada, Germany and the Netherlands as compared with the UK (figure 1). When 
analysed by geographical region, death or dependency was 50% lower in North 
America and North West Europe as compared with the British Isles (p<0.0001) (figure 
2). The significant difference in outcome between North America and the British Isles 
remained following adjustment for case mix variables alone (model A), and case mix 
with indicators of clinical care (model B) (figure 2). 
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TABLE 3 
 
Outcome measured as death, death or dependency (mRS>2), length of stay in hospital, and institutionalisation, by country. 
Number (%) or median (interquartile range); comparison by Chi-square test or Kruskal-Wallis test. 
 
Country Bel 
gium 
Can 
ada 
Den 
mark 
Finland France Ger 
many 
Ireland Nether 
lands 
Norway Swede
n 
UK Total p 
Subjects 40 388 110 27 191 36 61 143 82 123 283 1484  
Dead              
Day 10 1  
(2.5) 
7  
(1.8) 
2 
(1.8) 
1  
(3.7) 
9  
(4.7) 
0  
(0) 
2  
(3.3) 
11  
(7.7) 
3  
(3.7) 
8  
(6.5) 
19  
(6.7) 
63  
(4.2) 
0.035 
Day 180 
(%) 
6  
(15.0) 
38  
(9.8) 
12  
(10.9) 
1 
 (3.7) 
32  
(16.8) 
0  
(0) 
13  
(21.3) 
31  
(21.7) 
8  
(9.8) 
16  
(13.0) 
58  
(20.5) 
215 
(14.5) 
0.0002 
mRS>2               
Day 180 
(%) 
23  
(57.5) 
185 
(47.7) 
55  
(50.0) 
16  
(59.3) 
119 
(62.3) 
16  
(44.4) 
41  
(67.2) 
73 
(51.0) 
46  
(56.1) 
77  
(62.6) 
179 
(63.3) 
830 
(55.9) 
0.0040 
Length of 
stay (days) 
23  
(14-
47) 
14  
(8-27) 
11  
(8-25) 
11  
(9-17) 
16  
(12-
22) 
21  
(15-
39) 
39  
(16-
78) 
19  
(12-
35) 
14  
(10-
20) 
17  
(10-35) 
27  
(10-
79) 
16  
(10-
34) 
<0.0001 
Institution 
(%) 
18  
(47.4) 
212 
(56.4) 
62  
(57.9) 
21  
(80.8) 
125 
(69.4) 
23  
(63.9) 
30  
(51.7) 
66  
(52.0) 
55  
(69.6) 
60  
(52.6) 
97  
(37.0) 
769 
(54.8) 
<0.0001 
 
mRS: modified Rankin Scale;  
 
 13 
Death 
The eleven countries differed in death rates by days 10 (end of treatment) and 180 
(Germany 0.0%, Netherlands 21.7%). The following case mix variables were 
associated with an increased risk of death in univariate analyses: increasing age, pre-
morbid disability, non-smoking, atrial fibrillation, prior stroke, diabetes mellitus, 
increasing stroke severity, and visible infarction on the CT scan. Measures of care 
were also associated with case fatality: use of compression stockings, lack of 
physiotherapy (all p<0.05, data not shown). Gender, race, blood pressure, admission 
to an ASU or SRU, speech therapy, and treatment with tinzaparin were not related to 
death. When assessing the effect of treatment on death by country no statistically 
significant effects were seen (data not shown).  
 
The hazard of death at 6 months differed significantly by country (p<0.0001); in 
comparison with the UK, death rates were lower in Canada, Denmark, Germany and 
Norway (figure 1). When grouped by geographical region, death rates were 40-50% 
lower in North America and Scandinavia than in the British Isles (p=0.0001) (figures 3 
and 4). The significant difference in case fatality remained after adjustment for case 
mix variables alone, and with service indicators (p<0.0001). 
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DISCUSSION 
 
The important finding in this study is that functional outcome and death after stroke 
differed significantly between the eleven countries, and geographical aggregates of 
these countries. In univariate analyses, both functional outcome and case fatality 
varied by a factor of two, a magnitude which is more powerful than treatment effects 
associated with stroke units and thrombolysis.[7, 14] Differences between countries 
have been observed in previous studies for both functional outcome [8, 10] and case 
fatality [2, 8, 10, 11] after stroke. 
 
Since case mix is well known to influence clinical outcome, variations in outcome will, 
at least in part, reflect differences in case mix.[15] Hence, studies comparing 
populations need to adjust for case mix [16, 17] although this is not without 
methodological problems and demands rigorous analysis.[15] In TAIST, differences in 
most baseline variables were present with some likely to be of significant clinical 
relevance, e.g. pre-morbid status, previous hypertension, atrial fibrillation and clinical 
stroke syndrome. Nevertheless, adjustment for  up to 13 prognostic factors did not 
remove differences in outcome between the countries. Similar adjustment for case 
mix, but using fewer prognostic variables, did not remove outcome differences in 
other studies.[8, 10] 
 
It is now realised that adjustment for prognostic clinical factors alone is insufficient; 
process of care (equating to quality of care) also needs to be included since these 
factors can have powerful effects on outcome.[18, 19] We included some such 
measures, including admission to a stroke unit, care by therapists and use of 
compression stockings. Again, adjustment for both case mix and these clinical process 
measures did not explain the differences in outcome seen in TAIST, a finding that was 
also seen in BIOMED and IST (although based on fewer variables).[8, 10] 
 
Explaining the residual differences between the countries after adjustment for case 
mix and process of care is difficult. The TAIST investigators were, in general, 
experienced in managing stroke and taking part in acute stroke trials, and cared for 
patients within the context of a stroke service. Furthermore, all patients had a CT scan 
prior to enrolment. A number of potential explanations exist relating to chance, 
systematic bias and confounding, as for any observational study that does not include 
consecutively admitted patients. 
 
First, the study was relatively large, and the differences profound and consistent both 
within (internal validity) and outwith (external validity) [2, 8, 10] the study so chance 
alone is unlikely. It maybe possible that the care received by patients in a clinical trial 
is different from routine stroke management. It is also possible that some centres 
may not be representative of their countries. However in analysing outcome by 
geographical regions with similar health services statistical power was increased 
thereby reducing the chance that unrepresentative centres may have affected the 
results.[11] We did not analyse outcome by centre since most recruited few patients 
thereby limiting the power of analyses.  
 
Second, the interpretation of definitions for case mix variables, quality markers and 
outcome might vary between countries leading to systematic bias. Our data came 
from an industry sponsored trial with a detailed protocol, and it is unlikely that 
interpretations in the definitions of clinical variables would differ significantly. There is 
some evidence that the interpretation of functional status may vary between 
countries.[20-22] If relevant, a systematic bias in the recording of both pre-morbid 
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and post-stroke mRS would be present and their relationship would be very strong, 
which was not the case in TAIST. Even if a bias in functional outcome was present, the 
between-country differences in case fatality, which were of comparable magnitude to 
those seen for functional outcome, cannot be explained in this manner. 
 
Third, unmeasured variation in case mix and/or processes of care may explain the 
observed differences.[23] IST, GAIN and BIOMED each reported limited numbers of 
case mix variables,[8, 10, 24] in contrast to our study which adjusted for pre-morbid 
function, co-morbid conditions, clinical process and brain imaging. However, the 
inclusion of these factors in the prognostic models was not helpful in explaining 
between-country differences in outcome. Whilst other case mix variables might 
explain some of the observed differences in outcome, it is unlikely that they would 
exert such a powerful effect individually.  
 
Finally, the differences seen in this study may relate to the quality of hyperacute and 
acute care, i.e. management within 48 hours post stroke. Patients who are monitored 
for, and maintain, physiological homeostasis (e.g. blood pressure, temperature, 
glucose) following acute stroke have an improved outcome.[25, 26] Some acute 
stroke patients may also benefit from interventions such as thrombolysis or 
neurosurgery [27] although these treatments were not given in TAIST. Health care 
models focussing on the hyperacute phase exist variably within countries but are less 
common in the British Isles than in North America and much of Western Europe. For 
example, interventions to alter abnormal physiological parameters occur less 
frequently in the UK.[8] Nevertheless, this explanation for the differences in outcome 
seen in TAIST are largely hypothetical and randomised controlled trials examining the 
roles of intensive monitoring and physiological intervention are required.[28] Further 
evidence could also be obtained from observational studies on consecutively admitted 
patients with data on basic physiological interventions in the acute phase. 
 
 
In summary, we have shown that outcome from stroke varies significantly between 
countries using prospective data from a large multicentre international acute stroke 
trial. Correction for case mix and markers of service provision did not explain these 
differences. 
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FIGURE 1 
 
Hazard ratio (HR) of death, and odds ratio (OR) of a poor functional outcome (dead or 
dependent, modified Rankin Score 3-6), with 95% confidence intervals, at 180 days 
by country, relative to UK (adjusted for treatment group, tinzaparin, aspirin) 
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FIGURE 2 
 
Odds ratio (95% confidence intervals) of a poor outcome (dead or dependent, 
modified Rankin Score 3-6) at day 180 by geographical region, relative to British Isles. 
Crude and adjusted rates given. 
 
All models include adjustment for TAIST treatment group 
Model A, case mix: age, gender, race, current smoking, diabetes mellitus, previous 
stroke, systolic blood pressure, atrial fibrillation, severity (SSS), infarct on baseline CT 
scan, prior modified Rankin Scale, time to treatment 
Model B, case mix and clinical care: model A, plus care in an Acute Stroke Unit, care in 
a Stroke Rehabilitation Unit, physiotherapy, speech therapy, stockings 
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FIGURE 3 
 
Hazard ratio (95% confidence intervals) of death at 6 months by geographical region, 
relative to British Isles. Crude and adjusted rates given. 
 
All models include adjustment for TAIST treatment group 
Model A, case mix: age, gender, race, current smoking, diabetes mellitus, previous 
stroke, systolic blood pressure, atrial fibrillation, severity (SSS), infarct on baseline CT 
scan, prior modified Rankin Scale, time to treatment 
Model B, case mix and clinical care: model A, plus care in an Acute Stroke Unit, care in 
a Stroke Rehabilitation Unit, physiotherapy, speech therapy, stockings 
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FIGURE 4 
 
Kaplan-Meier survival plot for the five geographical regions. 
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